Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 4/20 | 0.54 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.51 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.51 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.48 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3857718 | 1.00 | GRIK1 (0.54) | GRIK1GRIK2CA2MAPK1SLC1A2 | |
| SCHEMBL3785993 | 1.00 | GRIK1 (0.54) | GRIK1GRIK2CA2MAPK1SLC1A2 | |
| SCHEMBL7550232 | 1.00 | GRIK1 (0.54) | GRIK1GRIK2CA2MAPK1SLC1A2 | |
| SCHEMBL7552503 | 1.00 | GRIK1 (0.54) | GRIK1GRIK2CA2MAPK1SLC1A2 | |
| SCHEMBL19306557 | 0.98 | CA2 (0.53) | GRIK1GRIK2CA2MAPK1SLC1A2 | |
| SCHEMBL7552288 | 0.98 | CA2 (0.53) | GRIK1GRIK2CA2MAPK1SLC1A2 | |
| SCHEMBL3839934 | 0.98 | CA2 (0.53) | GRIK1GRIK2CA2MAPK1SLC1A2 | |
| SCHEMBL7551496 | 0.92 | CA2 (0.61) | GRIK1GRIK2CA2MAPK1SLC1A2 | |
| SCHEMBL6271522 | 0.85 | CA2 (0.47) | GRIK1GRIK2CA2SLC1A2SLC1A1 | |
| SCHEMBL7557794 | 0.84 | CHRM1 (0.62) | GRIK1GRIK2CA2MAPK1SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020156320-A1 | Enantioselective synthesis of valproic acid analogues | NAU HEINZ (DE) | 2002-10-24 | — | — | US | claimed |
| US-20220175776-A1 | COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS | Frequency Therapeutics, Inc. (US) | 2022-06-09 | — | — | US | disclosed |
| CN-114340611-A | Combination of CHIR99021 and valproic acid for the treatment of hearing loss | 频率医疗公司 | 2022-04-12 | — | — | CN | disclosed |
| US-11260130-B2 | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV | Frequency Therapeutics, Inc. (US) | 2022-03-01 | — | — | US | disclosed |
| EP-3952854-A1 | COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS | Frequency Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20210300948-A1 | 1H-PYRROLE-2,5-DIONE COMPOUNDS AND METHODS OF USING THEM TO INDUCE SELF-RENEWAL OF STEM/PROGENITOR SUPPORTING CELLS | Frequency Therapeutics, Inc. | 2021-09-30 | — | — | US | disclosed |
| US-11066419-B2 | 1H-pyrrole-2,5-dione compounds and methods of using same | Frequency Therapeutics, Inc. (US) | 2021-07-20 | — | — | US | disclosed |
| US-11033546-B2 | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: I | Frequency Therapeutics, Inc. (US) | 2021-06-15 | — | — | US | disclosed |
| WO-2020210388-A1 | COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS | Frequency Therapeutics, Inc. (US) | 2020-10-15 | — | — | WO | disclosed |
| US-20200316089-A1 | 1,2-DIHYDRO-3H-PYRAZOL-3-ONE COMPOUNDS AND METHODS OF USING SAME | Frequency Therapeutics, Inc. | 2020-10-08 | — | — | US | disclosed |
| US-7589221-B2 | Industrial scale process; treats neurodegenerative diseases; high optical purity; less dangerous reaction | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-09-15 | — | — | US | disclosed |
| US-20070043114-A1 | Nerve regeneration promoters | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1685832-A1 | NERVE REGENERATION PROMOTERS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-08-02 | — | — | EP | disclosed |
| US-20060135802-A1 | Process for producing (2r)-2-propyloctanoic acid and intermediate therefor | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1078921-B1 | NOVEL INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF OPTICALLY ACTIVE OCTANOIC ACID DERIVATIVES | ONO PHARMACEUTICAL CO (JP) | 2003-03-26 | — | — | EP | disclosed |
| US-20020156320-A1 | Enantioselective synthesis of valproic acid analogues | NAU HEINZ (DE) | 2002-10-24 | — | — | US | disclosed |
| US-6392073-B1 | IMPROVED OPTICAL PURITY OVER RECRYSTALLIZATION METHOD; 2.10 CAMPHORSULTAM DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-05-21 | — | — | US | disclosed |
| US-20020028947-A1 | Novel intermediates and processes for the preparation of optically active octanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2002-03-07 | — | — | US | disclosed |
| US-6333415-B1 | N-(2S-(2-(PROPENYL OR PROPYNYL OR PROPYL)) OCTANOYL) (1S)-(-)-2,10-CAMPHORSULTAM, TO PREPARE 2S-(2-(PROPENYL OR PROPYNYL OR PROPYL)) OCTANOIC ACID, | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-12-25 | — | — | US | disclosed |
| EP-1078921-A1 | NOVEL INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF OPTICALLY ACTIVE OCTANOIC ACID DERIVATIVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043114-A1 | Nerve regeneration promoters | BDNF, NGF, GAP43 | GRIK1 1591/4885GRIK2 1779/4885CA2 4138/4885 |
| US-20020156320-A1 | Enantioselective synthesis of valproic acid analogues | COASY, ACADM, CYP2A6 | GRIK1 668/4885GRIK2 452/4885CA2 460/4885 |
| US-20020028947-A1 | Novel intermediates and processes for the preparation of optically active octanoic acid derivatives | PDE6H, PDE6C, PDE6D | GRIK1 880/4885GRIK2 627/4885CA2 1578/4885 |
| US-20210300948-A1 | 1H-PYRROLE-2,5-DIONE COMPOUNDS AND METHODS OF USING THEM TO INDUCE SELF-RENEWAL OF STEM/PROGENITOR SUPPORTING CELLS | MCL1, PROX1, MKI67 | GRIK1 3223/4885GRIK2 3098/4885CA2 4491/4885 |
| US-20200316089-A1 | 1,2-DIHYDRO-3H-PYRAZOL-3-ONE COMPOUNDS AND METHODS OF USING SAME | DCX, MCL1, MKI67 | GRIK1 1547/4885GRIK2 1977/4885CA2 4492/4885 |
| US-20220175776-A1 | COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS | HES1, SHH, HDAC11 | GRIK1 157/4885GRIK2 286/4885CA2 425/4885 |
| US-11033546-B2 | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: I | GSK3B, GSK3A, GSKIP | GRIK1 2378/4885GRIK2 2732/4885CA2 1639/4885 |
| US-11066419-B2 | 1H-pyrrole-2,5-dione compounds and methods of using same | MKI67, PROX1, DCX | GRIK1 3429/4885GRIK2 3099/4885CA2 4161/4885 |
| US-20060135802-A1 | Process for producing (2r)-2-propyloctanoic acid and intermediate therefor | CYP51A1, POR, GRHPR | GRIK1 1627/4885GRIK2 1239/4885CA2 723/4885 |
| US-11260130-B2 | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV | GSK3B, GSK3A, GSKIP | GRIK1 2770/4885GRIK2 2882/4885CA2 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.